Talyst Announces GRIFOLS Reseller Agreement
KIRKLAND, Wash., Dec. 9, 2013
KIRKLAND, Wash., Dec. 9, 2013 /PRNewswire/ -- "As we continue to focus on
engineering the safer pharmacy, we constantly evaluate what we view as 'Best
of Breed' Integration Partners to extend the products and solutions we deliver
to our customers," said Carla Corkern, Chief Executive Officer of Talyst. "We
have found that with GRIFOLS, and their Phocus Rx^®, Remote IV Compounding
Validation product. Talyst has reached an agreement to sell the Phocus Rx^®
product to existing and new customers." Phocus Rx^® is the only non-invasive
camera system designed for use in compounding area with any type of hood or
open compounding environment.
"We look forward to working with the GRIFOLS team in integrating their Phocus
Rx^® product into Talyst's AutoPharm Enterprise Solution, as we both continue
to focus on enhanced workflow efficiency, and improved patient safety," said
Scott Starke, General Manager of Talyst's Acute Care business segment.
"GRIFOLS is proud to be a part of this initiative," said Juan M. Cana, General
Manager of GRIFOLS USA Hospital Division. "Throughout the following years, we
look forward to collaborating with the Talyst team in providing technology
systems specially designed to enhance efficiency and increase the safety of
sterile preparations in hospital pharmacy."
Talyst is a leader in pharmacy automation and engineers the safer pharmacy.
Our solutions provide enterprise-wide medication management across your entire
health system to offer greater inventory control, enhanced workflow
efficiency, and improved patient safety. As of 2013, Talyst has installed
automated systems in more than 700 integrated healthcare systems, acute-care
hospitals, long-term care facilities, and correctional institutions. We offer
a powerful software platform with a suite of hardware components to meet your
specific needs. Follow us on Twitter @Talyst_Inc or visit us at
GRIFOLS is a global healthcare company with a 70-year legacy of improving
people's health and well-being through the development of life-saving plasma
medicines, hospital pharmacy products, and diagnostic technology for clinical
use. GRIFOLS USA Hospital Division provides simple, cost-effective solutions
to operational challenges in pharmacy. Its primary focus is on the sterile IV
preparation area. Providing a wide range of hardware, software and disposable
products for hospital pharmacies, GRIFOLS develops technology systems designed
to increase the safety of sterile preparations and clean room solutions in
In 2012, GRIFOLS' sales exceeded 2,620 million euros. The company's class A
shares are listed on the Spanish Stock Exchange, where they form part of the
Ibex-35 (MCE:GRF). Its non-voting class B shares are listed on the Mercado
Continuo (MCE:GRF.P) and on the US NASDAQ via ADRs (NASDAQ: GRFS). For more
information visit www.grifols.com.
Contact: Talyst, (425) 289-5400, email@example.com
Press spacebar to pause and continue. Press esc to stop.